Get the Stockscreener App
231.95
0.39%
0.90
Natera Inc stock is traded at $231.95, with a volume of 1.34M.
It is up +0.39% in the last 24 hours and up +10.72% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$231.05
Open:
$231.5
24h Volume:
1.34M
Relative Volume:
1.02
Market Cap:
$32.35B
Revenue:
$1.96B
Net Income/Loss:
$-253.24M
P/E Ratio:
-122.00
EPS:
-1.9012
Net Cash Flow:
$94.06M
1W Performance:
-5.15%
1M Performance:
+10.72%
6M Performance:
+41.13%
1Y Performance:
+39.35%
1-Day Range:
$225.58
$232.23
1-Week Range:
$225.58
$246.90
52-Week Range:
$125.38
$246.90
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
231.95 | 32.22B | 1.96B | -253.24M | 94.06M | -1.9012 |
|
TMO
Thermo Fisher Scientific Inc
|
572.28 | 217.50B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.33 | 164.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
704.20 | 56.49B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
139.68 | 40.44B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
222.26 | 38.48B | 15.90B | 1.28B | 2.21B | 7.2842 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Natera, Inc. $NTRA Shares Bought by Nikko Asset Management Americas Inc. - MarketBeat
Engineers Gate Manager LP Sells 30,042 Shares of Natera, Inc. $NTRA - MarketBeat
GCM Grosvenor Holdings LLC Sells 6,475 Shares of Natera, Inc. $NTRA - MarketBeat
Gilder Gagnon Howe & Co. LLC Decreases Stake in Natera, Inc. $NTRA - MarketBeat
Bellevue Group AG Raises Stock Position in Natera, Inc. $NTRA - MarketBeat
AQR Capital Management LLC Boosts Holdings in Natera, Inc. $NTRA - MarketBeat
Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Exelixis (EXEL) and Natera (NTRA) - The Globe and Mail
Caption Management LLC Takes Position in Natera, Inc. $NTRA - MarketBeat
Natera (NTRA) Joins Phase II Breast Cancer Study with Innovative DNA Testing - GuruFocus
Maverick Capital Ltd. Reduces Position in Natera, Inc. $NTRA - MarketBeat
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer - Yahoo Finance
Natera Completes Acquisition Of Foresight Diagnostics For Up To $450 Million - Pulse 2.0
Natera New Test Data Could Change How Doctors Manage Breast Cancer - Benzinga
Is It Too Late to Consider Natera After a 511% Three Year Surge? - simplywall.st
Natera stock rating reiterated at Buy by TD Cowen on solid momentum - Investing.com India
Is It Too Late To Consider Natera After Its Recent 12.8% Price Surge? - Yahoo Finance
California Public Employees Retirement System Purchases 29,296 Shares of Natera, Inc. $NTRA - MarketBeat
Frontier Capital Management Co. LLC Has $65.04 Million Position in Natera, Inc. $NTRA - MarketBeat
Natera, Inc. $NTRA Shares Sold by Amundi - MarketBeat
Natera (NTRA) Unveils Promising Results from Phase III Breast Ca - GuruFocus
Natera (NASDAQ: NTRA) PALLAS: Signatera MRD‑positive group shows 13.4‑21.5 hazard ratios - Stock Titan
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer - Yahoo Finance
Natera acquires Foresight Diagnostics for up to $450M - MedTech Dive
Preimplantation Genetics Diagnosis Market size to exceed - openPR.com
Natera, Inc. $NTRA Stake Lowered by Blue Water Life Science Advisors LP - MarketBeat
Cerity Partners LLC Boosts Holdings in Natera, Inc. $NTRA - MarketBeat
Natera director Chapman sells shares for $1.06 million - Investing.com
What's Driving the Market Sentiment Around Natera Inc? - Benzinga
Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna Makes New $1.24 Million Investment in Natera, Inc. $NTRA - MarketBeat
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting - marketscreener.com
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera - Wilson Sonsini
Natera's (NTRA) Buy Rating Reiterated at Canaccord Genuity Group - MarketBeat
Natera, Inc. Stock (NTRA) Opinions on Foresight Acquisition and Signatera Data - Quiver Quantitative
BTIG Research Boosts Natera (NASDAQ:NTRA) Price Target to $260.00 - MarketBeat
Natera stock rises after Canaccord reiterates Buy rating following Foresight acquisition - Investing.com UK
Guggenheim Capital LLC Sells 4,628 Shares of Natera, Inc. $NTRA - MarketBeat
Natera purchases Foresight Diagnostics - Yahoo Finance
Natera Makes High-Conviction Moves to Seize the Lucrative Oncology Frontier; Will It Succeed? - Smartkarma
Federated Hermes Inc. Has $129.71 Million Position in Natera, Inc. $NTRA - MarketBeat
Jump Financial LLC Purchases 18,821 Shares of Natera, Inc. $NTRA - MarketBeat
Invesco Ltd. Sells 165,294 Shares of Natera, Inc. $NTRA - MarketBeat
Natera Acquires Foresight Diagnostics - Oncodaily
Natera acquires Foresight Diagnostics to expand cancer detection capabilities By Investing.com - Investing.com Nigeria
Should Natera’s (NTRA) New Share Offering and Signatera Lymphoma Data Require Action From Investors? - simplywall.st
Dir Chapman Files To Sell 4,366 Of Natera Inc [NTRA] - TradingView
Natera envisions cancer-testing future with $450M Foresight buy - BioWorld MedTech
Boulder diagnostics co. bought by Austin biotech giant in $450M deal - The Business Journals
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal? - Benzinga
Working capital per share of Natera, Inc. – DUS:45E - TradingView
Natera buys Foresight Diagnostics in cancer testing deal worth up to $450M - Fierce Biotech
Austin biotech giant Natera acquires Colorado diagnostics company - The Business Journals
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):